Clinical trials: Neuroectodermal Tumor
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Pheochromocytoma, Neuroblastoma
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
- Conditions
- Pheochromocytoma, Neuroblastoma, Paraganglioma, Medullary Thyroid Carcinoma
- Trial name
- NCT01373736
- Testing
- 123I-meta-iodobenzylguanidine
- Where
- Canada
- Sponsor
- Vancouver Coastal Health
Medulloblastoma
Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults
The purpose of this study is to determine whether a combination of a radiochemotherapy (vincristin) and a following maintenance chemotherapy (vincristin, cisplatin and CCNU) in adult patients with medulloblastoma is tolerable.
- Trial name
- NOA-07 (NCT01614132)
- Testing
- maintenance chemotherapy (vincristin, cisplatin and CCNU), Radiotherapy
- Where
- 15 sites in Germany
- Volunteers
- 33 people
- Sponsor
- University of Regensburg
Glioblastoma Multiforme
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
This is a prospective, open-label, single arm, historical control pilot study aimed to test the effectiveness and safety of TTFields delivered through high intensity arrays in recurrent glioblastoma.
- Trial name
- NCT04492163
- Testing
- TTFields
- Where
- Czechia
- Volunteers
- 25 people
- Sponsor
- NovoCure GmbH
Glioblastoma
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
This study is an open-label, first-in-human, dose-escalation study of CV09050101 mRNA vaccine (CVGBM) in patients with newly diagnosed "MGMT-unmethylated" Glioblastoma (GBM).
- Trial name
- NCT05938387
- Testing
- CV09050101 mRNA vaccine (CVGBM) 12 μg, CV09050101 mRNA vaccine (CVGBM) 25 μg, CV09050101 mRNA vaccine (CVGBM) 50 μg
- Where
- 13 sites in Belgium, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- CureVac
Melanoma
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without…
- Trial name
- MelPORT (NCT04594187)
- Testing
- Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Pediatric Retinoblastoma, Retinoblastoma
Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
The purpose of this study is to see if there is a difference between the development of the brain (neurodevelopment) in children who have been treated for retinoblastoma with multiple anesthetic exposures, compared with brain…
- Trial name
- NCT03546387
- Testing
- Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V), California Verbal Learning Test, Children's Version, Beery Developmental Test of Visual Motor Integration, 6th edition
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Neuroblastoma
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma
Neuroblastoma is the second most frequent cause for death from cancer in childhood. Already one year after diagnosis of recurrence from high risk neuroblastoma, 75% of the patients experience further progression.
- Trial name
- METRO-NB2012 (NCT02641314)
- Testing
- metronomic therapy
- Where
- 8 sites in Germany
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Melanoma
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC. Two question are aimed to be answered by this study: 1.
- Trial name
- ChemoSensMM (NCT00779714)
- Testing
- DTIC (dacarbazine), paclitaxel + cisplatin, treosulfan + cytarabine
- Where
- 23 sites in Germany
- Volunteers
- 360 people
- Sponsor
- University of Wuerzburg
Glioblastoma, GBM
Surgical Nivolumab And Ipilimumab For Recurrent GBM
This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.
- Conditions
- Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
- Trial name
- NCT04606316
- Testing
- Nivolumab, Ipilimumab, Surgery
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Gilbert Youssef
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC)
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
This is a prospective, multi-centre, open-label, single-arm, stratified, exploratory, Phase 2 study evaluating the efficacy and safety of 177Lu-DOTATATE in combination with nivolumab in adult patients with Grade 3 neuroendocrine…
- Trial name
- NCT04525638
- Testing
- 177Lu-Dotatate, Nivolumab
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de investigación HM
Heathy Volunteer, Parkinsonian Syndromes
Ultralow Dose PET Imaging of 18F-FDOPA
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring.
- Conditions
- Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
- Trial name
- NCT07542158
- Testing
- 18F-FDOPA
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Retinoblastoma
Deep Learning in Retinoblastoma Detection and Monitoring.
Retinoblastoma is the most common eye cancer of childhood. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment.
- Trial name
- NCT05308043
- Testing
- Deep learning algorism
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Tongren Hospital
Neoplasms, Glioblastoma
Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner
Glioblastoma multiforme (GBM) is the most common malignant central nervous system (CNS) tumor in adulthood with a median survival of 12-16 months.
- Trial name
- TOGETHER (NCT02129335)
- Testing
- stress
- Where
- 3 sites in Switzerland
- Volunteers
- 12 people
- Sponsor
- University Hospital, Basel, Switzerland
Glioblastoma
Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma
Despite an aggressive therapeutic approach, the prognosis for most patients with glioblastoma (GBM) remains poor. The relationship between non-invasive Magnetic Resonance Imaging (MRI) biomarkers at preoperative, postradiotherapy…
- Trial name
- ONCOhabitats (NCT03439332)
- Where
- Spain
- Volunteers
- 305 people
- Sponsor
- Juan M Garcia-Gomez
Malignant Melanoma
Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma
Postoperative complications like seroma formation and wound site infection readily occur following completion axillary lymph node dissection (ALND) for malignant melanoma.
- Trial name
- NCT04648163
- Where
- Austria
- Volunteers
- 118 people
- Sponsor
- Medical University of Graz
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Melanoma, Cancer Survivorship
Mentored Community Gardening for Individuals With Skin Cancer
The investigators will conduct a single-arm pilot feasibility trial of mentored community gardening for melanoma survivors integrating dosimeters and accelerometers.
- Conditions
- Melanoma, Cancer Survivorship, Skin Cancer, Basal Cell Carcinoma
- Trial name
- H4H2-AZ (NCT05648604)
- Testing
- Mentored Community Gardening
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Melanoma
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma
This is a monocentric prospective study. This study aims to investigate the prognostic value of the novel melanin-targeted imaging modality 18F-PFPN PET in patients with melanoma and seek independent prognostic factors for…
- Trial name
- NCT05645484
- Testing
- 18F-PFPN, 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology